<DOC>
	<DOCNO>NCT00003754</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may kill tumor cell stop growth new blood vessel tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining thalidomide chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine thalidomide cyclophosphamide treat child recurrent refractory childhood cancer .</brief_summary>
	<brief_title>Thalidomide Cyclophosphamide Treating Children With Recurrent Refractory Childhood Cancers</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy toxic effect thalidomide cyclophosphamide patient recurrent refractory pediatric malignancy . OUTLINE : Patients receive oral thalidomide 4 time daily . Cyclophosphamide administer IV 1 hour every 4 week , begin day thalidomide . Treatment continue absence unacceptable toxicity disease progression . Tumor response assess every 3 month . PROJECTED ACCRUAL : A total 45-80 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven pediatric malignancy , except appearance consistent brainstem tumor MRI , tumor marker positive germ cell tumor , ophthalmologic diagnosis intraocular retinoblastoma Failed conventional treatment conventional therapy available Measurable disease MRI , CT scan , biochemical tumor marker , cytology , bone marrow examination PATIENT CHARACTERISTICS : Age : Not specify Performance status : Lansky 60100 % OR Karnofsky 60100 % Life expectancy : At least 6 week Hematopoietic : Absolute neutrophil count least 750/mm3 ( 300750/mm3 , due bone marrow infiltration malignancy ) Platelet count least 75,000/mm3 ( 20,00075,000/mm3 , due bone marrow infiltration malignancy ) Hepatic : Bilirubin le 2.0 mg/dL ALT le 3 time upper limit normal ( ULN ) Renal : Creatinine le 2 time ULN OR Creatinine clearance least 70 mL/min Neurologic : No peripheral neuropathy grade 3 4 No seizure disorder patient without CNS malignancies Other : Not pregnant nursing Negative pregnancy test study 1 month final dose thalidomide Fertile patient must use effective contraception least 1 month study PRIOR CONCURRENT THERAPY : See Disease Characteristics No limit number prior agent regimens receive Biologic therapy : Prior bone marrow transplantation allow Chemotherapy : Recovered prior chemotherapy No prior thalidomide Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 4 week since prior major surgery ( 2 week minor surgery , exclude central venous catheter placement procedure )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>